Journal article
Polyunsaturated fatty acid intake and risk of cardiovascular mortality in a low fish-consuming population: a prospective cohort analysis
AJ Owen, DJ Magliano, K O’Dea, ELM Barr, JE Shaw
European Journal of Nutrition | SPRINGER HEIDELBERG | Published : 2016
Abstract
Purpose: The aim of this study was to examine the relationship between polyunsaturated fatty acids (PUFA) intake (n-6 and n-3) and mortality in a population-based sample with a low fish intake. Methods: Cox regression was used to examine the relationships between dietary PUFA intake and all-cause or CVD mortality in the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) cohort, a population of 11,247 Australians aged ≥25 years recruited in 1999/2000 and followed until 2012. Demographic, lifestyle and behavioural information were collected by questionnaire and fasting blood tests undertaken. Dietary intake was collected by a 121-item food frequency questionnaire. Vital status and caus..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The AusDiab Study co-coordinated by the Baker IDI Heart and Diabetes Institute gratefully acknowledges the contribution of the study participants. In addition, AusDiab acknowledges the funding and in-kind support provided by the Australian National Health and Medical Research Council (NHMRC Grants 233200 and 1007544), Australian Government Department of Health and Ageing, Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, Amgen Australia, AstraZeneca, Bristol-Myers Squibb, City Health Centre-Diabetes Service-Canberra, Department of Health and Community Services-Northern Territory, Department of Health and Human Services-Tasmania, Department of Health-New South Wales, Department of Health-Western Australia, Department of Health-South Australia, Department of Human Services-Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian & FH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer Pty Ltd, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital, Sydney, Sanofi Aventis, sanofi-synthelabo and the Victorian Government's OIS Program. JS is supported by a National Health and Medical Research Council Fellowship.